川宁生物：业绩持续高增长，期待合成生物品种贡献增量

Investment Rating - The investment rating for the company is "Buy - A" with a target price of 12.73 CNY for the next six months [6][9]. Core Views - The company has demonstrated sustained high growth in its performance, with a significant increase in revenue and net profit driven by strong market demand for antibiotics and ongoing process optimization [2][4]. - The company is actively advancing its synthetic biology projects, with several products already in various stages of production and commercialization [5]. Financial Performance - In H1 2024, the company achieved a revenue of 3.195 billion CNY, representing a year-on-year growth of 32.20%. The net profit attributable to shareholders was 766 million CNY, up 96.05% year-on-year [2]. - The Q2 2024 gross margin was 36.13%, an increase of 5.25 percentage points year-on-year, while the net profit margin reached 24.74%, up 5.97 percentage points year-on-year [3]. Product Segmentation - The revenue breakdown for H1 2024 shows that the main products include thiocyanate red mycin (29.15%), cephalosporin intermediates (23.48%), and penicillin intermediates (40.72%) [2]. Cost Management - The company has effectively optimized its production processes, leading to increased output and reduced costs, which has positively impacted profit margins [4]. Synthetic Biology Projects - The company has a rich pipeline of synthetic biology projects, with products like red myrtenol and 5-hydroxytryptophan already in production stages, indicating a strong potential for future revenue growth [5]. Future Projections - Revenue growth is projected at 24.3%, 13.0%, and 7.9% for 2024 to 2026, respectively, with net profit growth expected at 50.4%, 20.3%, and 13.1% during the same period [9][10].